Article
First-generation epidermal growth factor receptor inhibitors in non-small cell lung cancer: clinical impact of the epidermal growth factor receptor fluorescence in situ hybridization assay.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer - 1 Jun 2008
Hirsch Fred R, Dziadziuszko Rafal, Varella-Garcia Marileila, Franklin Wilbur A, Gandara David R, Bunn Paul A
Abstract excerpt
Epidermal growth factor receptor (EGFR) inhibitors have been proven to improve survival in advanced non-small cell lung cancer patients, even after failure of previous chemotherapy. However, how to identify the patients, who will benefit from this treatment, is still not known. Clinical and demographic factors, i.e., females, never-smokers, patients with Asian ethnicity, or histology of adenocarcinoma, seem all...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.